Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
Arvinas (Nasdaq: ARVN), a clinical-stage biotechnology company focused on developing targeted protein degradation drugs, has announced its upcoming third quarter 2024 financial results and corporate update webcast. The event is scheduled for Wednesday, October 30, 2024, at 8:00 a.m. ET.
Investors and interested parties can access the live webcast through the 'Events and Presentations' section on the company's investor page. For those unable to attend the live event, a replay will be made available on the Arvinas website following the presentation.
Arvinas (Nasdaq: ARVN), una società biotecnologica in fase clinica focalizzata sullo sviluppo di farmaci per la degradazione mirata delle proteine, ha annunciato il prossimo webcast sui risultati finanziari e sull'aggiornamento aziendale per il terzo trimestre del 2024. L'evento è programmato per mercoledì 30 ottobre 2024, alle 8:00 AM ET.
Gli investitori e le parti interessate possono accedere al webcast dal vivo tramite la sezione 'Eventi e Presentazioni' nella pagina dedicata agli investitori dell'azienda. Per coloro che non possono partecipare all'evento dal vivo, una replica sarà disponibile sul sito di Arvinas dopo la presentazione.
Arvinas (Nasdaq: ARVN), una empresa biotecnológica en etapa clínica centrada en el desarrollo de medicamentos para la degradación selectiva de proteínas, ha anunciado su próxima transmisión web de resultados financieros y actualización corporativa del tercer trimestre de 2024. El evento está programado para miércoles 30 de octubre de 2024, a las 8:00 AM ET.
Los inversores y las partes interesadas pueden acceder a la retransmisión en vivo a través de la sección 'Eventos y Presentaciones' en la página de inversores de la empresa. Para aquellos que no puedan asistir al evento en vivo, se hará disponible una repetición en el sitio web de Arvinas después de la presentación.
Arvinas (Nasdaq: ARVN), 표적 단백질 분해 약물 개발에 주력하는 임상 단계의 생명공학 회사가 2024년 3분기 재무 결과 및 기업 업데이트 웨비나를 발표했습니다. 이 행사는 2024년 10월 30일 수요일 오전 8시 ET에 예정되어 있습니다.
투자자와 이해관계자는 회사의 투자자 페이지에 있는 '이벤트 및 프레젠테이션' 섹션을 통해 실시간 웨비나에 접속할 수 있습니다. 라이브 행사에 참석할 수 없는 분들을 위해 프레젠테이션 후 Arvinas 웹사이트에서 재생할 수 있는 녹화본이 제공될 예정입니다.
Arvinas (Nasdaq: ARVN), une entreprise de biotechnologie en phase clinique spécialisée dans le développement de médicaments de dégradation protéique ciblée, a annoncé la prochaine diffusion de ses résultats financiers du troisième trimestre 2024 et la mise à jour de l'entreprise. L'événement est prévu pour mercredi 30 octobre 2024, à 8h00 ET.
Les investisseurs et les parties intéressées peuvent accéder au webcast en direct via la section 'Événements et Présentations' sur la page des investisseurs de l'entreprise. Pour ceux qui ne peuvent pas assister à l'événement en direct, un enregistrement sera disponible sur le site Web d'Arvinas après la présentation.
Arvinas (Nasdaq: ARVN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Medikamenten zur gezielten Proteinabbau konzentriert, hat sein bevorstehendes Webcast zu den Finanzergebnissen und Unternehmensupdates für das dritte Quartal 2024 angekündigt. Die Veranstaltung ist für Mittwoch, den 30. Oktober 2024, um 8:00 Uhr ET geplant.
Investoren und Interessierte können über den Bereich 'Veranstaltungen und Präsentationen' auf der Investoren-Seite des Unternehmens auf das Live-Webcast zugreifen. Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird eine Wiederholung nach der Präsentation auf der Arvinas-Website verfügbar sein.
- None.
- None.
NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2024 financial results and provide a corporate update during a live webcast on Wednesday, October 30, 2024, at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website following the completion of the event.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When will Arvinas (ARVN) report its Q3 2024 financial results?
How can I access Arvinas' (ARVN) Q3 2024 earnings webcast?
Will there be a replay available for Arvinas' (ARVN) Q3 2024 earnings call?
